Open, prospective, multi-center, two-part study of patient preference with monthly ibandronate therapy in women with postmenopausal osteoporosis switched from daily or weekly alendronate or risendronate-BONCURE: Results of Turkish sub-study

Simple item page
dc.contributor.authorEskiyurt N.
dc.contributor.authorIrdesel J.
dc.contributor.authorSepici V.
dc.contributor.authorUǧurlu H.
dc.contributor.authorKirazli Y.
dc.contributor.authorArdiç F.
dc.contributor.authorBütün B.
dc.contributor.authorAkyüz G.
dc.contributor.authorCerrahoǧlu L.
dc.contributor.authorŞendur Ö.F.
dc.contributor.authorYalçin P.
dc.contributor.authorÖncel S.
dc.contributor.authorSaridoǧan M.
dc.contributor.authorSarpel T.
dc.contributor.authorTosun M.
dc.contributor.authorKutsal Y.G.
dc.contributor.authorŞenel K.
dc.contributor.authorGürsoy S.
dc.contributor.authorCantürk F.
dc.contributor.authorDemir H.
dc.contributor.authorÖzdener F.
dc.contributor.authorÖncel H.
dc.date.accessioned2024-07-22T08:19:49Z
dc.date.available2024-07-22T08:19:49Z
dc.date.issued2012
dc.description.abstractAim: BONCURE (Bonviva for Current Bisphosphonate Users Regional European Trial), aimed to evaluate patient preference with monthly ibandronate in women with postmenopausal osteoporosis who previously received daily or weekly alendronate or risendronate. Materials and Methods: This prospective, open-label study consisted of two sequential stages, Part A (screening) and Part B (treatment). Patients enrolled into Part A completed the Candidate Identification Questionnaire (CIQ). In Part B, after completing the Osteoporosis Patient Satisfaction Questionnaire (OPSAT-Q), patients received monthly oral ibandronate 150 mg for 6 months. Following treatment, patients completed the OPSAT-Q and Preference Questionnaire. Results: A total of 223 patients (mean age, 63.7±9.51 years) were enrolled in Part A from Turkey. Among them, 103 (46.2%) answered "YES" to at leastone CIQ question. The mean composite OPSAT-Q domain scores increased for convenience (mean change, 15.3±17.7 points), quality of life (10.4±20.4points), overall satisfaction (11.9±22.7 points), and side effects (3.3±18.8 points). At month 6, 177 subjects (92.7%) preferred once-monthly dosing scheduleand 99.0% were compliant (≥80%) with study treatment. Thirty (15.6%) subjects experienced mild to moderate adverse events, mostly gastrointestinal. Conclusion: Postmenopausal women with osteoporosis prefer and are more satisfied and compliant with monthly dosing of ibandronate than daily or weekly bisphosphonate treatment.
dc.identifier.DOI-ID10.4274/tod.29491
dc.identifier.issn21463816
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/17862
dc.language.isoEnglish
dc.publisherGalenos Yayincilik,
dc.rightsAll Open Access; Gold Open Access
dc.subjectalendronic acid
dc.subjectangiotensin II antagonist
dc.subjectanilide
dc.subjectbeta adrenergic receptor blocking agent
dc.subjectcalcium
dc.subjectdihydropyridine derivative
dc.subjectdipeptidyl carboxypeptidase inhibitor
dc.subjectdiuretic agent
dc.subjecthydroxymethylglutaryl coenzyme A reductase inhibitor
dc.subjectibandronic acid
dc.subjectrisedronic acid
dc.subjectsalicylic acid
dc.subjectsalicylic acid derivative
dc.subjectserotonin uptake inhibitor
dc.subjectvitamin D
dc.subjectvitamin D derivative
dc.subjectabdominal pain
dc.subjectadult
dc.subjectaged
dc.subjectarticle
dc.subjectCandidate Identification Questionnaire
dc.subjectconnective tissue disease
dc.subjectdrug efficacy
dc.subjectdrug intoxication
dc.subjectdrug safety
dc.subjectdrug substitution
dc.subjectdrug tolerability
dc.subjectdrug withdrawal
dc.subjectdyspepsia
dc.subjectfemale
dc.subjectgastrointestinal disease
dc.subjectgastrointestinal symptom
dc.subjecthernia
dc.subjecthuman
dc.subjectinfection
dc.subjectinfestation
dc.subjectinjury
dc.subjectlung embolism
dc.subjectmajor clinical study
dc.subjectmetabolic disorder
dc.subjectmulticenter study
dc.subjectmusculoskeletal disease
dc.subjectnausea
dc.subjectnutritional disorder
dc.subjectopen study
dc.subjectOsteoporosis Patient Satisfaction Questionnaire
dc.subjectpatient compliance
dc.subjectpatient preference
dc.subjectpatient satisfaction
dc.subjectpostmenopause osteoporosis
dc.subjectprospective study
dc.subjectquality of life
dc.subjectquestionnaire
dc.subjectscoring system
dc.subjectscreening test
dc.subjectstomach upset
dc.subjecttreatment duration
dc.subjecttreatment outcome
dc.subjectTurkey (republic)
dc.titleOpen, prospective, multi-center, two-part study of patient preference with monthly ibandronate therapy in women with postmenopausal osteoporosis switched from daily or weekly alendronate or risendronate-BONCURE: Results of Turkish sub-study
dc.typeArticle

Files

Collections

Scopus Koleksiyonu